DK2364084T3 - Farmaceutiske sammensætninger med lavdosis liponsyre og fremgangsmåder - Google Patents

Farmaceutiske sammensætninger med lavdosis liponsyre og fremgangsmåder Download PDF

Info

Publication number
DK2364084T3
DK2364084T3 DK09825441.0T DK09825441T DK2364084T3 DK 2364084 T3 DK2364084 T3 DK 2364084T3 DK 09825441 T DK09825441 T DK 09825441T DK 2364084 T3 DK2364084 T3 DK 2364084T3
Authority
DK
Denmark
Prior art keywords
lens
pharmaceutical composition
lipoic acid
age
cells
Prior art date
Application number
DK09825441.0T
Other languages
English (en)
Inventor
William Garner
Margaret Garner
Original Assignee
Encore Health Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encore Health Llc filed Critical Encore Health Llc
Application granted granted Critical
Publication of DK2364084T3 publication Critical patent/DK2364084T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (11)

1. Farmaceutisk sammensætning til okular anvendelse omfattende aktivstof som er: 5-(l,2-dithiolan-3-yl)pentansyre; 6,8-dimercaptooctanonsyre; dihydrolipoat; 5-(l,2-thiaselenolan-5-yl)penta nsyre, 5-(l,2-thiaselenolan-3-yl)penta nsyre; eller et salt eller ester deraf, i en mængde på 10 til 250 μΜ og mindst én farmaceutisk acceptabel bærer.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor aktivstoffet er til stede i en mængde på 10 til 100 μΜ.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor aktivstoffet er 5-(l,2-dithiolan-3-yl)pentansyre eller et salt eller ester deraf.
4. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor aktivstoffet er R-enantiomeren.
5. Farmaceutisk sammensætning til anvendelse ifølge krav 1, omfattende en emulgator og en bufret bærer.
6. Farmaceutisk sammensætning ifølge kravene 1 til 5 til anvendelse i forebyggelse eller behandling af iltningsbeskadigelse af celler.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, yderligere omfattende en kemisk energikilde til simultan eller fortløbende anvendelse med aktivstoffet.
8. Farmaceutisk sammensætning ifølge krav 7, hvor den aktive kemiske energikilde administreres simultant med aktivstoffet.
9. Farmaceutisk sammensætning til anvendelse ifølge krav 8, hvor den kemiske energikilde er glucose eller NADPH.
10. Farmaceutisk sammensætning ifølge krav 6, hvor behandlingen yderligere omfatter tilførsel af energi for at fremme brydning af disulfidbindinger.
11. Farmaceutisk sammensætning ifølge krav 6, hvor cellerne er okularceller.
DK09825441.0T 2008-11-07 2009-11-06 Farmaceutiske sammensætninger med lavdosis liponsyre og fremgangsmåder DK2364084T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/267,208 US9044439B2 (en) 2008-03-05 2008-11-07 Low dose lipoic and pharmaceutical compositions and methods
PCT/US2009/063469 WO2010054135A1 (en) 2008-11-07 2009-11-06 Low dose lipoic acid pharmaceutical compositions and methods

Publications (1)

Publication Number Publication Date
DK2364084T3 true DK2364084T3 (da) 2016-01-25

Family

ID=41054317

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09825441.0T DK2364084T3 (da) 2008-11-07 2009-11-06 Farmaceutiske sammensætninger med lavdosis liponsyre og fremgangsmåder

Country Status (8)

Country Link
US (2) US9044439B2 (da)
EP (2) EP2939539B1 (da)
CA (1) CA2742973C (da)
DK (1) DK2364084T3 (da)
ES (2) ES2681477T3 (da)
HK (1) HK1212157A1 (da)
PL (1) PL2364084T3 (da)
WO (1) WO2010054135A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8102027B2 (en) * 2007-08-21 2012-01-24 Broadcom Corporation IC package sacrificial structures for crack propagation confinement
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
DK2442647T3 (da) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivater deraf og anvendelser af disse
US8410162B2 (en) 2009-06-15 2013-04-02 Encore Health Llc Choline esters
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
AU2013332247B2 (en) 2012-10-17 2018-11-29 Brien Holden Vision Institute Limited Lenses, devices, methods and systems for refractive error
RU2735790C2 (ru) * 2014-03-03 2020-11-09 Энкор Вижн, Инк. Композиции и способы применения холинового эфира липоевой кислоты
CA3136938A1 (en) * 2019-04-17 2020-10-22 Santen Pharmaceutical Co., Ltd. Lipoic acid prodrug
CN113387923A (zh) 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935962A (en) * 1960-06-17 1963-09-04 Fujisawa Pharmaceutical Co Improvements in or relating to the production of 6.8-dithiooctanamides
US3855240A (en) * 1969-04-28 1974-12-17 Exxon Research Engineering Co Sulfur containing heterocycles
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
US4755528A (en) * 1984-12-06 1988-07-05 Alcon Laboratories, Inc. High energy ionizing protective 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and N-acyl and N-alkyl derivatives thereof, compositions and method of use therefor
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
WO1993002639A1 (en) * 1991-08-06 1993-02-18 Autogenesis Technologies, Inc. Injectable collagen-based compositions for making intraocular lens
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4633793A (en) 1992-06-10 1994-01-04 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
WO1994001096A1 (en) * 1992-07-02 1994-01-20 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6313274B1 (en) 1992-07-06 2001-11-06 Thomas R. Sykes Photoactivation of proteins for conjugation purposes
US5354331A (en) * 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
US5465737A (en) * 1992-07-15 1995-11-14 Schachar; Ronald A. Treatment of presbyopia and other eye disorders
ES2133411T3 (es) * 1992-08-07 1999-09-16 Keravision Inc Anillo corneal intraestromal.
DE4345199C2 (de) * 1993-05-22 1995-10-12 Asta Medica Ag Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
US5395356A (en) * 1993-06-04 1995-03-07 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
US5527774A (en) * 1993-07-12 1996-06-18 Girard; Louis J. Dislocation of cataractous lens by enzymatic zonulolysis
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
JPH09511507A (ja) * 1994-04-04 1997-11-18 フリーマン，ウイリアム・アール 上昇した眼圧を治療するためのホスホニルメトキシアルキルヌクレオシドの使用
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5686450A (en) * 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
US6007510A (en) * 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US5843184A (en) * 1998-01-26 1998-12-01 Cionni; Robert J. Endocapsular tension ring and method of implanting same
US6153647A (en) 1998-11-12 2000-11-28 My-Tech, Inc. Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
US6472541B2 (en) * 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
AU758903B2 (en) * 1998-11-26 2003-04-03 Pentapharm Ag Transport system conjugate
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU5601300A (en) * 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
JP2004509856A (ja) * 2000-08-02 2004-04-02 ビーエーエスエフ　アクチェンゲゼルシャフト リポ酸およびジヒドロリポ酸の製造方法
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
AU2001283386A1 (en) 2000-08-16 2002-02-25 Refocus, Llc. Presbyopia treatment by lens alteration
US6923955B2 (en) * 2000-08-16 2005-08-02 Newlens, Llc Presbyopia treatment by lens alteration
US20050112113A1 (en) 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
DE10045059A1 (de) * 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
EP1370237A2 (en) 2001-01-19 2003-12-17 Newlens, LLC Presbyopia treatment by lens alteration
ATE446949T1 (de) * 2001-03-19 2009-11-15 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
WO2002096360A2 (en) * 2001-05-25 2002-12-05 Ceremedix, Inc. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
WO2003084532A1 (en) 2002-04-03 2003-10-16 Avery Mitchell A Lipoic acid analogs useful as provitamins and antioxidants
US20050137124A1 (en) * 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
CN100367949C (zh) * 2002-09-13 2008-02-13 有限会社绪方研究 黑色素消除制剂
JP2006504701A (ja) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US7585846B2 (en) 2003-11-25 2009-09-08 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060188492A1 (en) * 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
EP1904108B1 (en) 2005-07-15 2011-11-30 Chakshu Research, Inc. Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
US20070055070A1 (en) * 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
WO2007149313A1 (en) * 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
WO2008103370A1 (en) * 2007-02-22 2008-08-28 Children's Hospital And Research Center At Oakland Fatty acid formulations and methods of use thereof
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
UA86441C2 (ru) 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
DK2442647T3 (da) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivater deraf og anvendelser af disse
US8410162B2 (en) 2009-06-15 2013-04-02 Encore Health Llc Choline esters

Also Published As

Publication number Publication date
US9517225B2 (en) 2016-12-13
CA2742973C (en) 2017-05-23
EP2939539A1 (en) 2015-11-04
ES2681477T3 (es) 2018-09-13
EP2364084A1 (en) 2011-09-14
US20150297561A1 (en) 2015-10-22
PL2364084T3 (pl) 2016-06-30
CA2742973A1 (en) 2010-05-14
EP2364084B1 (en) 2016-01-06
HK1212157A1 (en) 2016-06-10
ES2561600T3 (es) 2016-02-29
WO2010054135A1 (en) 2010-05-14
US9044439B2 (en) 2015-06-02
US20090227677A1 (en) 2009-09-10
EP2364084A4 (en) 2012-05-23
EP2939539B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
DK2364084T3 (da) Farmaceutiske sammensætninger med lavdosis liponsyre og fremgangsmåder
US8647612B2 (en) Dithiol compounds, derivatives, and treatment of presbyopia
US8697109B2 (en) Caged mercaptan and seleno-mercaptan compounds and methods of using them
Abdelkader et al. Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens
JP5583310B2 (ja) 眼球の症状の予防及び治療のための眼科用製剤
US9161931B2 (en) Dithiol compounds and treatment of presbyopia using said compounds
WO1997018817A1 (fr) Preparation externe contenant de la vitamine d ou de la vitamine k
CN109908140A (zh) 生物素治疗多发性硬化的用途
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
US11298337B2 (en) Parthenolide and its derivative for use in the treatment of axonal damage
EP0815862A1 (en) Ophthalmological composition comprising activated vitamin d
KR20150126021A (ko) 다이피리다몰을 이용하여 눈 장애를 치료하는데 사용하기 위한 조성물
EP1750770B1 (fr) Utilisation de composes organo-silicies pour contraindre des tissus conjonctifs leses
JPWO2018030389A1 (ja) Ｎａｄ関連代謝産物の利用
Koide et al. Ascorbic acid concentration in rabbit vitreous measured by microdialysis with HPLC-electrochemical detection before and after vitreous surgery
JP2002514937A (ja) 創傷を治癒する組成物を含むレザーカートリッジ
RU2612810C2 (ru) Способ применения нестероидных противовоспалительных средств в эксимерлазерной хирургии роговицы
JPH0327314A (ja) ヒトの眼の処置用組成物
JP5680420B2 (ja) 紫外線防止剤
CN115006404A (zh) 一种具有视神经保护功效的药物组合物及其应用
ESTERS PATENT APPLICATION
JPH09157165A (ja) 点眼薬及び白内障の遅延・治療用剤